221 related articles for article (PubMed ID: 35884434)
1. Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.
Matsumae T; Kodama T; Myojin Y; Maesaka K; Sakamori R; Takuwa A; Oku K; Motooka D; Sawai Y; Oshita M; Nakabori T; Ohkawa K; Miyazaki M; Tanaka S; Mita E; Tawara S; Yakushijin T; Nozaki Y; Hagiwara H; Tahata Y; Yamada R; Hikita H; Tatsumi T; Takehara T
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884434
[TBL] [Abstract][Full Text] [Related]
2. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
[TBL] [Abstract][Full Text] [Related]
3. Circulating DNA changes are predictive of disease progression after transarterial chemoembolization.
Sefrioui D; Verdier V; Savoye-Collet C; Beaussire L; Ghomadi S; Gangloff A; Goria O; Riachi G; Montialoux H; Schwarz L; Tuech JJ; Frebourg T; Michel P; Sarafan-Vasseur N; Di Fiore F
Int J Cancer; 2022 Feb; 150(3):532-541. PubMed ID: 34622951
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.
Myojin Y; Kodama T; Sakamori R; Maesaka K; Matsumae T; Sawai Y; Imai Y; Ohkawa K; Miyazaki M; Tanaka S; Mita E; Tawara S; Yakushijin T; Nozaki Y; Hagiwara H; Tahata Y; Yamada R; Hikita H; Tatsumi T; Takehara T
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205631
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma.
An Y; Guan Y; Xu Y; Han Y; Wu C; Bao C; Zhou B; Wang H; Zhang M; Liu W; Qiu L; Han Z; Chen Y; Xia X; Wang J; Liu Z; Huang W; Yi X; Huang J
Am J Transl Res; 2019; 11(10):6462-6474. PubMed ID: 31737198
[TBL] [Abstract][Full Text] [Related]
8. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
[TBL] [Abstract][Full Text] [Related]
10. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma.
Nakatsuka T; Nakagawa H; Hayata Y; Wake T; Yamada T; Nishibatake Kinoshita M; Nakagomi R; Sato M; Minami T; Uchino K; Enooku K; Kudo Y; Tanaka Y; Kishikawa T; Otsuka M; Tateishi R; Koike K
J Gastroenterol; 2021 May; 56(5):456-469. PubMed ID: 33712873
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
12. Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma.
Ge Z; Helmijr JCA; Jansen MPHM; Boor PPC; Noordam L; Peppelenbosch M; Kwekkeboom J; Kraan J; Sprengers D
Transl Oncol; 2021 Jul; 14(7):101073. PubMed ID: 33915518
[TBL] [Abstract][Full Text] [Related]
13. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
[TBL] [Abstract][Full Text] [Related]
14. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Mohamed YI; Duda DG; Awiwi MO; Lee SS; Altameemi L; Xiao L; Morris JS; Wolff RA; Elsayes KM; Hatia RI; Qayyum A; Chamseddine SM; Rashid A; Yao JC; Mahvash A; Hassan MM; Amin HM; Kaseb AO
Oncotarget; 2022 Dec; 13():1314-1321. PubMed ID: 36473155
[TBL] [Abstract][Full Text] [Related]
15. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
[TBL] [Abstract][Full Text] [Related]
16. Tumor steatosis and glutamine synthetase expression in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
Kurebayashi Y; Tsujikawa H; Sugimoto K; Yunaiyama D; Araki Y; Saito K; Takahashi H; Kakegawa T; Wada T; Tomita Y; Abe M; Yoshimasu Y; Takeuchi H; Hirata T; Sakamaki K; Kakimi K; Nagao T; Itoi T; Sakamoto M
Hepatol Res; 2023 Oct; 53(10):1008-1020. PubMed ID: 37300323
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
[TBL] [Abstract][Full Text] [Related]
18. Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC).
Lee T; Rawding PA; Bu J; Hyun S; Rou W; Jeon H; Kim S; Lee B; Kubiatowicz LJ; Kim D; Hong S; Eun H
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565192
[TBL] [Abstract][Full Text] [Related]
19. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
[TBL] [Abstract][Full Text] [Related]
20. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]